Biocon Launches Breast Cancer Drug
  • Prabha Hedge
  • Jan 20 2014

January 20: Biocon announced the launch of CANMAb, a biosimilar for the treatment of breast cancer in India. CANMAb, being developed jointly by Biocon and Mylan under a global partnership, is the world's first biosimilar version of Roche's Herceptin.